Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018104561) ACYLATED GLP-1/GLP-2 DUAL AGONISTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/104561 International Application No.: PCT/EP2017/082290
Publication Date: 14.06.2018 International Filing Date: 11.12.2017
IPC:
C07K 14/605 (2006.01) ,A61K 38/26 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
605
Glucagons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
26
Glucagons
Applicants:
ZEALAND PHARMA A/S [DK/DK]; Smedeland 36 DK-2600 Glostrup, DK
Inventors:
DUE LARSEN, Bjarne; DK
GRIFFIN, Jonathan; SE
GIEHM, Lise; DK
EDWARDS, Alistair Vincent Gordon; DK
Agent:
HGF LIMITED; GB
Priority Data:
PA20160075709.12.2016DK
Title (EN) ACYLATED GLP-1/GLP-2 DUAL AGONISTS
(FR) AGONISTES DOUBLES DE GLP-1/GLP-2 ACYLÉS
Abstract:
(EN) The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
(FR) L'invention concerne des composés ayant une activité agoniste au niveau des récepteurs de GLP-1 (peptide 1 apparenté au glucagon) et de GLP-2 (peptide 2 apparenté au glucagon). Les composés trouvent une utilisation, entre autres, dans la prophylaxie ou le traitement d'un dommage intestinal et d'un dysfonctionnement, de la régulation du poids corporel et dans la prophylaxie ou le traitement d'un dysfonctionnement métabolique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)